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Abstract
Background: Breast cancer is a heterogeneous disease with several morphological and molecular subtypes. Widely
accepted molecular classification system uses assessment of estrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki67. Few studies have been conducted
on the incidence and molecular types of breast cancer in Sub-Saharan Africa. Previous studies mainly from Western
and Central Africa, showed breast cancer to occur at younger ages and to present with aggressive features, such as
high-grade, advanced stage and triple-negative phenotype (negative for ER, PR and HER2). Limited data from East
Africa including Ethiopia however shows hormone receptor negative tumors to account for a lower proportion of
all breast cancers than has been reported from elsewhere in Africa.
Methods: In this study from Tikur Anbessa Specialized Hospital, 114 breast cancer patients diagnosed between 2012
and 2015 were enrolled. ER, PR, Ki67 and HER2 receptor status were assessed using immunohistochemistry from tissue
microarrays. FISH was used for assessment of gene amplification in all equivocal tumor samples and for confirmation in
HER2-enriched cases.
Results: The distribution of molecular subtypes was: Luminal A: 40%; Luminal B: 26%; HER2-enriched: 10%; TNBC: 23%.
ER were positive in 65% of all tumors and 43% the cases were positive for PR. There was statistically significant difference
in median age at diagnosis between the molecular subtypes (P < 0.05). There was a bimodal distribution of molecular
subtypes in different age ranges with Luminal B subtype being more common at younger ages (median = 36) and
Luminal A subtype more prevalent at older ages (median = 42). There were no statistically significant differences in
tumor grade, histology, and stage between the molecular subtypes of breast cancer.
Conclusion: The present study detected Luminal A breast cancer to be the most common subtype and reveals
a relatively low rate of hormone receptor negative and TNBC. Our findings and results from other East African
studies suggest geographic variability in the distribution of the molecular subtypes of breast cancer in Africa
and hence have important clinical and policy implications for breast cancer control and treatment in Ethiopia.
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Background
Breast cancer is the most common malignant neoplasm
among women in Addis Ababa (Ethiopia). The Addis
Ababa Cancer registry reports that breast cancer ac-
counts for 34% of all female cancer cases, followed by
cervical cancer at 16% [1]. Although breast cancer has a
markedly higher incidence in developed countries, half
of new breast cancer diagnosis and about 60% of breast
cancer deaths occur in the developing world [2].
A significant increase in breast cancer incidence is re-
ported in most Sub-Saharan Africa countries suggesting
an increasing public health problem in a continent with
existing infrastructures having been developed mainly
for maternal, child health and infectious diseases [3].
Widespread urbanization, changing patterns of repro-
ductive and environmental risks factors, obesity, de-
creased physical activity, and increasing life expectancy
[3, 4] are among the salient factors implicated in the
steady rise in breast cancer incidence across low income
countries.
Breast cancer is a heterogeneous disease with differ-
ent morphological and molecular subtypes [5, 6]. The
morphological classification is still the foundation of
histopathological diagnosis, but in the era of modern
personalized medicine, a number of molecular classifi-
cation systems have been introduced. In this context,
estrogen receptor (ER) and progesterone receptor (PR)
analysis in breast carcinomas were the first established
biomarker assays with both prognostic and predictive
power and they have been in use since the 1970s [7].
Human Epidermal Growth Factor 2 (HER2) was dis-
covered in the 1990s and HER2-targeted therapy was
subsequently introduced; the introduction of targeted
antibodies that interfere with HER2 signaling followed
and their use has led to improved survival among
breast cancer patients whose tumors overexpress
HER2 [8].
Further studies have revealed distinct molecular sub-
types of breast cancer based upon the gene expression
profiling of tumors [9]. Since classifications based on
gene expression are still considered unaffordable in
most global settings outside high income countries of
the Western hemisphere, immunohistochemistry (IHC)
studies have gained widespread acceptance as potential
robust surrogates for more complex bar-code type as-
says. A combination of ER, PR, and HER2 defines the
molecular classes initially identified by gene expression
profile [10]. The classification systems used by Nielsen
[11], Sotiriou [12] and the St. Gallen international
panel of experts [13] in 2004, 2006, and 2011 respect-
ively are widely used among research communities.
The St. Gallen international panel of experts incorpo-
rated the well-established proliferation-associated anti-
gen Ki67 that may also provide additional prognostic
and predictive value to the previous classification sys-
tems [13, 14]. Several studies show that molecular sub-
types of breast cancer vary substantially in their
behavior and response to treatment [15]; however, at
present none of these schema are widely used outside
of Western countries.
With increasing opportunities for implementing mod-
ern health care in Sub-Saharan African countries, more
in-depth knowledge of African breast cancer molecular
characteristics compared to the more studied western
countries is essential for improving prognosis and man-
agement of breast cancer.
Few studies have been conducted in Africa on the clin-
icopathological and biological characteristics of breast
cancer in Sub-Saharan African countries. The published
studies conducted so far exhibit some degree of diver-
gence in their results. The majority of these studies,
reviewed by Brinton et al., were mainly carried out on
west and central Africa and reported that breast cancer
patients exhibit specific features compared to the west-
ern countries [16]. According to these authors, breast
cancer in Sub-Saharan Africa is reported to occur in
younger age and show more aggressive features such as
high-grade tumors and triple-negative phenotypes (nega-
tive for expression of ER and PR and for over-expression
of HER2) [16]. Similar patterns to these African studies
have been reported among African American women
with disproportionately high incidence of triple negative
phenotype as compared to White Americans [17–19].
Preliminary evidence, however, shows geographical di-
versity in the distribution of breast cancer molecular
subtypes in Sub-Saharan African region with the rate of
triple negative breast cancer reported to be relatively
lower in East Africa [20–22]. In the present study, we
aimed to study a large collection of cases from a major
Ethiopian institution where women are treated for breast
cancer and investigate the molecular subtypes using the
most recent receptor-based classification [13, 14].
Methods
Case selection
We performed a cross sectional, retrospective study of
women diagnosed with breast cancer that were treated
at the Oncology Centre in Tikur Anbessa Specialized
Hospital (TASH). The TASH is a reference centre for
cancer treatment in Ethiopia located in the capital Addis
Ababa, and it receives patients from all regions in the
country. The patients enrolled in the study consisted of
women with available archived surgical specimen at
TASH or St. Paul’s Hospital Millenium Medical College
(SPHMMC) which is also a referral hospital in the cap-
ital providing surgical service to breast cancer patients
in the country. Information about demographic data and
tumor characteristics were obtained from the patient
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medical records at TASH. The collected variables were
age, tumor type, grade and stage of disease.
Only patients having undergone surgery between 2012
and 2015 were included in the study because specimens
collected from patients before this period were assessed
to be missing or improperly stored at the hospitals. One
hundred eighty-nine patients were initially included in
the study but 66 cases were excluded because formalin-
fixed paraffin-embedded (FFPE) tissue was not available
in the pathology departments or the biopsy was not of
sufficient quality for the study.
The final cohort in the study consisted of 123 breast
cancer patients. All archived FFPE blocks were sectioned
and H&E stained and examined by a pathologist (TS) for
locating tumors in the block to be used for constructing
tissue microarray (TMA). After TMA construction 114
cases were judged to be evaluable.
Tissue microarray
Digital images for constructing tissue microarray (TMA)
were taken from slides scanned with a Pannoramic 250
digital scanner (3D HISTECH Ltd., Budapest, Hungary)
and representative areas selected from images using the
software program ‘Case viewer’ (3D HISTECH Ltd.,
Budapest, Hungary). TMA were constructed using the
TMA grand master automated system (3DHISTECH Ltd.,
Budapest, Hungary). 0.6 mm punch biopsies in triplicate
corresponding to the marked area were taken from donor
paraffin blocks and merged into TMA recipient paraffin
blocks.
Immunohistochemistry
Immunohistochemistry (IHC) was done in automated sys-
tem using the Dako Autostainer Link. Formalin fixed, par-
affin sections were cut at 4 μm and rehydrated to water.
Heat induced epitope retrieval was performed with FLEX
TRS High pH Retrieval buffer for 20 min. After peroxidase
blocking, the specific monoclonal antibodies were applied
at room temperature for 20 min. The FLEX + Rabbit En-
Vision System was used for detection. DAB chromogen
was then applied for 10 min. Slides were counterstained
with Mayers hematoxylin for 5 s and then dehydrated and
coverslipped. Slides were scanned on a Pannoramic 250
digital scanner (3D HISTECH Ltd., Budapest, Hungary)
and images scored using the software program ‘Case
viewer’ (3D HISTECH Ltd., Budapest, Hungary). Negative
controls were included in each staining run.
Sources and dilutions of primary antibodies
ER clone EP1, PR clone PgR1294, Ki67 clone Mib-1 and
HER2 Herceptest, all from Agilent Dako, USA and all
Ready-to-use were used.
Fluorescence in situ hybridization
Slides were deparaffinized, rinsed in absolute alcohol,
and air dried. The sections were then subjected to pre-
treatment according to the manufacturer’s protocol.
Slides were hybridized with a probe mix in HYBrite
(Vysis, Des Plaines, IL) where denaturation was set at
6 min at 73 °C and hybridization for 17 h at 37 °C. Probe
mixes used were PATHYVISION (HER-2/CEP17) FISH
Probe Kit from Abbott Molecular, Des Plaines, IL. Slides
were scanned on a Pannoramic MIDI digital scanner
(3D HISTECH Ltd., Budapest, Hungary) and images
scored using the software program ‘Case viewer’ (3D
HISTECH Ltd., Budapest, Hungary). 20 tumor cells were
evaluated for scoring.
Scoring of each marker
Tumors were considered positive for ER and PR when
at least 1% of the tumor cells showed nuclear staining
irrespective of intensity according to ASCO/CAP 2013
guidelines [23]. HER2 was graded based on recommen-
dations from Fitzgibbons et al. [24]. Grading for HER2
is based on the degree of membrane staining, on a scale
of 0–3+. Grades of 0–1+ are considered negative, a
grade of 2+ is equivocal, and a grade of 3+ is consid-
ered positive for HER2 labeling. Specimens with a
HER2:CEP17 ratios of ≥2:0 were scored as positive for
HER2 amplification (FISH-positive), and specimens
with a HER2:CEP17 ratio of < 2:0 were scored as nega-
tive for HER2 amplification (FISH-negative). For Ki67
evaluation a minimum of 500 cells were counted in hot
spots. A Ki67 cut-off point of 20% was defined as high
according to the St. Gallen international panel of ex-
perts’ recommendation [14].
Molecular sub-typing
Breast carcinoma was classified into the following four
sub-types according to St. Gallen international expert’s
consensus 2013 [14]: luminal A (ER and/or PR-positive,
HER2-negative and Ki67 < 20%), luminal B (ER and/or
PR-positive, HER2-positive OR ER and/or PR-positive,
HER2-negative and Ki67 ≥ 20%), HER2-enriched (ER
and PR-negative, HER2 positive) and triple-negative
(ER-negative, PR-negative and HER2-negative).
HER2-enriched cases were confirmed by FISH analysis.
Statistical analysis
Statistical analysis was done using SPSS for windows
version 21.Continous data are reported as mean ± SD or
Number (proportions). Skew distributions are reported
as the median value with minimum and maximum. All P
values are two tailed and P value < 0.05 was considered
statistically significant. Chi-square test and ANOVA
were used to determine the correlations.
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Results
Patients
There were 114 participants with evaluable samples in
this study. Mean age at diagnosis was 43 years (SD 14)
and median age was 40 (range 22–75). Most of the
participants (40%) were < 40 years old. About 31% of
the participants were ≥50 years and only 19% were 40–
49 years old. Table 1 shows basic pathological and mo-
lecular characteristics of the study subjects. ER positive
tumors represent 65% of the cases (Table 1). There
was no statistically significant difference in clinico-
pathological characteristics between ER positive and
ER negative tumors (Table 2).
Distribution of molecular subtypes
A total of 112 cases had complete data concerning IHC.
These cases were classified according to St. Gallen inter-
national classification system 2013 [14]. Table 3 shows
distribution of the molecular subtypes. The largest pro-
portions of cases were classified as Luminal A (40%).
Triple negative breast cancer represents 23% of all cases.
The median ages at diagnosis across the molecular sub-
types were statistically significantly variable (P < 0.05) with
42, 36, 40, and 45 for Luminal A, Luminal B, HER2-
enriched and TNBC TNBC. Table 4 and Fig. 1 show an
earlier onset of luminal B compared to the other molecular
subtypes and compares frequencies across the molecular
subtypes. The frequencies of the different molecular sub-
types were statistically significantly different in different
age ranges (P < 0.05). It also reveals a decline in luminal B
subtypes as patients age increase with the incidence of lu-
minal A exceeding it at the age ranges > = 50.
Table 5 shows the distribution of clinicopathological
parameters in each molecular subtype. There was no
statistically significant difference in the distribution of
the clinicopathological parameters between the differ-
ent molecular subtypes of the tumors.
Table 1 Baseline clinicopathological and molecular





























Table 2 Association between ER expression and








Tumor Grade, n (%)
I 5(10) 2(7) 7(9)
II 18(36) 14(50) 32(41) 0.480
III 27(54) 12(43) 39(50)
Stage, n (%)
I 13(20) 6(19) 19(20)
II 27(42) 10(31) 37(39) 0.639
III 22(34) 14(44) 36(37)
IV 2(3) 2(6) 4(4)
Histological Type, n (%)
Infiltrating ductal 41(60) 26(80) 67(68) 0.123
Lobular 6(10) 0(0) 6(6)
Others/Not classified 18(30) 7(20) 25(26)
Table 3 Molecular Subtypes of breast Cancer
Molecular Subtypes Cases, n Percent
Luminal A 45 40
Luminal B 30 26
HER2-enriched 11 10
Triple Negative/Basal like 26 23
Missing 2 2
Total 114 100.0
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Discussion
Progress in molecular research have led to the classifica-
tion of breast cancers into distinct subgroups (luminal,
normal breast-like, Her2/neu-positive and basal-like sub-
types) based on mRNA expression profiles [25]. However,
gene expression profiling using cDNA microarray or RNA
seq technology is not currently feasible in clinical settings
due to its high cost and technical complexity. Therefore,
IHC markers have been validated and used as surrogates
for cDNA microarray in molecular subtyping of breast
cancer [26].
In the present study, we found that luminal A subtype
was the most prevalent followed by luminal B subtype,
Triple Negative, and HER2-enriched derived exclusively.
Our findings, from TMA IHC, are in contrast to most
other studies performed in standard paraffin sections, in
tissues from Sub-Saharan Africa particularly in west and
central African countries where triple negative pheno-
type was reported to be the most common molecular
subtype (43–82%) of breast cancer [16]. In Europe,
North America, Asia and middle eastern countries, 30–
70% of breast cancers are luminal A tumors and our re-
sult (40%) is comparable to the distribution seen in the
western societies [27, 28]. However, Luminal B which is
the second most common molecular subtype in our
study (26%) is present at higher proportion among our
study participants when compared to the rate seen in
the Western high resource regions, Asia and middle east
(10–20%) [27, 28].
A previous study among Ethiopian women carried
out by Kantelhardt [20] in 2014 compared ER negativ-
ity in 352 patients out of 1208 consecutive patients
treated at Addis Ababa-University Hospital, Ethiopia,
from June 2005 through December 2010. They re-
ported ER negative tumors to be around 35% in agree-
ment with our present results [20]. A comparable
result was also reported in a recent study done by
groups at the University of Michigan in 2016 from one
of the referral hospitals in Addis Ababa where they
found ER negative tumors to be 26.5% [22].
A study among women of East African origin in US, in
which a majority of the subjects (74%) were Ethiopians
living in the United States, reported estrogen receptor
negative tumors at 22% [29]. Similarly, recent studies in
Kenya reported estrogen receptor negative tumor at
27.2% [21]. These few studies among East Africans, as
well as our present study, which are summarized in
Table 6 suggest the existence of geographical diversity in
the distribution of molecular subtypes of breast cancer
in Sub-Saharan Africa. These findings indicate that the
frequency of ER negative tumors in East Africa may not
be different from that found in the Western countries
which is between 20 to 30% [15].
Similarly the frequencies of triple negative tumors in
these East African studies were lower than reported
from west and central Africa. TNBC in the Kenyan study
was reported in 20.2% of all cases [21] and TNBC in the
Michigan study among Ethiopian women was reported
Table 4 Frequency distribution of the molecular subtypesof the study participants in different age range
Age at diagnosis Molecular Subtypes p-value
Luminal A Luminal B HER2-enriched Triple Negative/ basal-like Total
< 40 16 19 4 8 47 0.031
40–49 5 6 4 8 23
> = 50 18 4 2 7 31
Fig. 1 Percentage distribution of the molecular subtypes of breast cancer in different age groups. The figure shows a Luminal B peak for participants
in < 40 age range and Luminal A peaks in the age range > =50. Triple negative/basal-like breast cancer is more common among participants between
the age of 40 and 49
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to be around 15% which is lower than our finding (23%),
but all of these studies indicate TNBC tumors to be less
common than reported elsewhere in Africa. Hence,
taken together, the data from East Africa suggest that it
would not be accurate to associate African ancestry with
increased probability of diagnosis with ER negative or
TNBC tumors, as the Sub-Saharan African populations
are known to be themselves highly heterogeneous in life-
styles, exposures, and genetic admixtures.
Present study has shown HER2 positivity at a slightly
lower proportion than the rate seen among Ethiopians
in the Michigan study [22] study (33%), the only other
study (to our knowledge) which has incorporated HER2
assessment for molecular phenotyping of breast cancer
from Ethiopia. However, HER2 positivity in our study
(23%) is comparable to white Americans, African Ameri-
cans, and West Africans which is about 17%, 19% and
20% respectively [22].
Our result shows an earlier onset of luminal B com-
pared to the other molecular subtypes with statistically
significant difference in median age at diagnosis
(P < 0.05). The median age at diagnosis in our study also
reveals a decline in luminal B subtypes as patients’ age
increase with the incidence of luminal A exceeding that
of luminal B at age ranges > = 50. This finding is com-
parable to a studies in the west where a bimodal age dis-
tribution at diagnosis is seen where incidence of the
more aggressive phenotype luminal B peaks at earlier
ages whereas luminal A type peaks at older ages [30].
The median age at diagnosis in our study was com-
parable to most previous studies in Africa and the few
studies done among breast cancer patients in Ethiopia
[20, 22]. However, it is much lower than the median
age at diagnosis in most Western countries which is
(55–60 years) [31]. The difference could be explained
by the fact that African nations have younger popula-
tion pyramids and the proportions reported in this and
earlier studies are not age adjusted so the distributions
are expected to always be shifted to younger ages in
African cases compared to the cases in western
Table 5 Distribution of Clinicopathological parameters in each molecular subtypes of breast cancer among the study participants
Clinico-pathological Parameters Luminal A Luminal B HER2-enriched Triple Negative Total p-value
Median age at diagnosis(min-max) 47(22–75) 35(22–53) 41(27–65) 46(29–60) 0.009
Tumor grade, n (%)
I 5(18) 0(0) 1(13) 1(6) 7(9)
II 11(39) 8(36) 5(63) 7(39) 31(41) 0.243
III 12(43) 14(64) 2(25) 10(55) 38(50)
Stage, n (%)
I 9(24) 5(19) 1(11) 4(18) 19(20)
II 13(35) 13(48) 1(11) 9(41) 36(38) 0.632
III 14(38) 8(30) 6(67) 8(36) 36(38)
IV 1(3) 1(4) 1(11) 1(5) 4(4)
Histological type, n (%)
Ductal 29(70) 15(60) 7(80) 17(80) 66(69) 0.708
Lobular 2(10) 4(10) 0(0) 0(0) 6(6)
Others/Unknown 9(20) 8(30) 2(20) 5(20) 24(25)
Table 6 Comparison of distribution of Molecular subtypes of Breast Cancer from Selected East African Studies













This Study, Endale et al. Ethiopia 114 43 35 56 76 23
Jiagge et al., 2016 [22] Ethiopia 94 43 – – – 15
Sayed S et al.,2014 [21] Kenya 301 47.5 27.2 35.2 82.4a 20.2
Kantelhardt et al., 2014 [20] Ethiopia 352 – 35 49 – –
Jemal and Fedewa, 2012 [29] USAb 186 48 22 35 – –
aHER2 equivocal cases are considered as negative
bDone on Eastern Africa-born blacks living in USA (74% were Ethiopians)
Hadgu et al. BMC Women's Health  (2018) 18:40 Page 6 of 8
countries; only 5% of African population is older than
60 years as compared to 24% of the population of
Europe [32] being > 60 years old. More extensive
population based registries in Africa, with active regis-
tration of cases, are urgently needed to understand the
burden of cancer and to aid in cancer control program.
Gaining a better understanding of environmental and
lifestyle risk factors is crucial, as the incidence of
breast cancer appears to be increasing at all ages in all
African regions.
There was no statistically significant difference be-
tween median age at diagnosis and the ER status of
breast cancer in this study. In this study, invasive ductal
carcinoma was the predominant histological type (60%),
which is comparable to the study by Kantelhardt in 2014
[20]. No statistically significant correlation was found
between the molecular subtypes of breast cancer and
histological type of breast cancer in this study, although
the numbers of non ductal histologies were very low in
the study. High tumor grade (Grade III) was reported in
34% of our study participants which is comparable with
the study done by Kantelhardt [20]. The increased rate
of high grade tumors observed in this study is in part
possibly due to late diagnosis of breast cancer. No statis-
tically significant correlation was found between the mo-
lecular subtypes of breast cancer and tumor grade in
this study. The numbers of cases in each category were
likely too small to appreciate differences, if they exist.
Limitations of the present study include selection
bias which is due to enrollment of participants with
available FFPE in the pathology laboratory, missing
clinicopathological information and small sample size.
Larger studies from population based samples are ne-
cessary to help guide cancer control programs. In spite
of its stated limitations, our study adds strength to the
notion that investments in utilization of hormonal and
anti-HER2 therapies have potential to impact survival
in Ethiopia, so efforts to spread education about imple-
menting these strategies are recommended in light of
the relatively high proportion of tumors amenable to
these treatments.
Conclusion
In conclusion, our study confirms the findings of stud-
ies from Ethiopia and other East African countries
that hormone receptor negative tumors are not the
most common molecular subtypes of breast cancer in
this particular part of Africa. Hence, majority of breast
cancer cases in this population may benefit from hor-
mone therapy and/or anti-HER2 or other targeted
therapy. Additionally, our findings and other East
African Studies confirm the geographic variability in
the distribution of the molecular subtypes of breast
cancer in Africa and hence have important clinical and
policy implications for breast cancer control. Further-
more, Ethiopian breast cancer patients exhibit highly
proliferative Luminal B tumors at young ages. Future
research should examine currently recognized as well
as novel genetic and environmental factors that may
contribute to the tumor characteristic differences
between different populations in Africa.
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